InFUSing Antisense Oligonucleotides for Treating ALS

Overview

Journal Trends Mol Med

Specialties General Medicine
Molecular Biology

Date 2022 Mar 5

PMID 35246398

Authors

Philippe Codron

Julien Cassereau

Patrick Vourch

Affiliations

Soon will be listed here.

Abstract

The question of a loss or toxic gain of function in FUS-related amyotrophic lateral sclerosis is still debated. Recently, Korobeynikov et al. argued that FUS mutations lead to a gain of function and showed that lowering wild-type and mutant FUS levels could be a promising therapeutic strategy.

Citing Articles

Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease.

Ou K, Jia Q, Li D, Li S, Li X, Yin P Transl Neurodegener. 2025; 14(1):4.

PMID: 39838446 PMC: 11748355. DOI: 10.1186/s40035-025-00466-9.

Clinical and Genetic Aspects of Juvenile Amyotrophic Lateral Sclerosis: A Promising Era Emerges.

Souza P, Serrano P, Farias I, Machado R, Badia B, de Oliveira H Genes (Basel). 2024; 15(3).

PMID: 38540369 PMC: 10969870. DOI: 10.3390/genes15030311.

Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice.

Takeuchi T, Maeta K, Ding X, Oe Y, Takeda A, Inoue M Mol Ther Nucleic Acids. 2023; 31:353-366.

PMID: 36817728 PMC: 9925842. DOI: 10.1016/j.omtn.2023.01.006.

Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives.

Lejman J, Panuciak K, Nowicka E, Mastalerczyk A, Wojciechowska K, Lejman M Int J Mol Sci. 2023; 24(2).

PMID: 36674643 PMC: 9860634. DOI: 10.3390/ijms24021130.